JP2021527083A5 - - Google Patents
Info
- Publication number
- JP2021527083A5 JP2021527083A5 JP2020568781A JP2020568781A JP2021527083A5 JP 2021527083 A5 JP2021527083 A5 JP 2021527083A5 JP 2020568781 A JP2020568781 A JP 2020568781A JP 2020568781 A JP2020568781 A JP 2020568781A JP 2021527083 A5 JP2021527083 A5 JP 2021527083A5
- Authority
- JP
- Japan
- Prior art keywords
- formulation
- polypeptide
- formulation according
- administered
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862684385P | 2018-06-13 | 2018-06-13 | |
| US62/684,385 | 2018-06-13 | ||
| US201962800808P | 2019-02-04 | 2019-02-04 | |
| US62/800,808 | 2019-02-04 | ||
| US201962855170P | 2019-05-31 | 2019-05-31 | |
| US62/855,170 | 2019-05-31 | ||
| PCT/US2019/036725 WO2019241353A1 (en) | 2018-06-13 | 2019-06-12 | Treatment of stage iii nsclc and mitigation of pathological conditions associated with the treatment |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2021527083A JP2021527083A (ja) | 2021-10-11 |
| JP2021527083A5 true JP2021527083A5 (enExample) | 2022-08-23 |
Family
ID=68843181
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568781A Pending JP2021527083A (ja) | 2018-06-13 | 2019-06-12 | ステージｉｉｉ ｎｓｃｌｃの治療及びその治療に伴う病理学的状態の鎮静 |
Country Status (14)
| Country | Link |
|---|---|
| US (1) | US20210113656A1 (enExample) |
| EP (1) | EP3806842A4 (enExample) |
| JP (1) | JP2021527083A (enExample) |
| KR (1) | KR20210020098A (enExample) |
| CN (1) | CN112566634A (enExample) |
| AU (1) | AU2019284765A1 (enExample) |
| BR (1) | BR112020025452A2 (enExample) |
| CA (1) | CA3103245A1 (enExample) |
| CL (1) | CL2020003204A1 (enExample) |
| IL (1) | IL279353A (enExample) |
| MX (1) | MX2020013535A (enExample) |
| SG (1) | SG11202012426WA (enExample) |
| TW (1) | TW202011954A (enExample) |
| WO (1) | WO2019241353A1 (enExample) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019299318A1 (en) * | 2018-07-02 | 2021-01-21 | Merck Patent Gmbh | Combination therapy with targeted TGF-B inhibition for treatment of advanced non-small cell lung cancer |
| WO2021209458A1 (en) * | 2020-04-14 | 2021-10-21 | Ares Trading S.A. | Combination treatment of cancer |
| EP4194468A4 (en) * | 2020-08-07 | 2025-07-16 | Bio Thera Solutions Ltd | ANTI PD-L1 ANTIBODY AND ITS USE |
| EP4583880A1 (en) * | 2022-09-09 | 2025-07-16 | Astrazeneca AB | Compositions and methods for treating advanced solid tumors |
| EP4676977A1 (en) * | 2023-03-09 | 2026-01-14 | Telix Pharmaceuticals (Innovations) Pty Ltd | Multifunctional antibodies |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| BR112016014952A2 (pt) * | 2014-02-10 | 2017-09-19 | Merck Patent Gmbh | Inibição direcionada de tgfbeta |
| RU2714233C2 (ru) * | 2015-02-26 | 2020-02-13 | Мерк Патент Гмбх | Ингибиторы pd-1 / pd-l1 для лечения рака |
| US20180064662A1 (en) * | 2015-03-05 | 2018-03-08 | The General Hospital Corporation | Novel compositions and uses of metformin agents |
| AU2017310027A1 (en) * | 2016-08-12 | 2019-01-31 | Merck Patent Gmbh | Combination therapy for cancer |
-
2019
- 2019-06-12 JP JP2020568781A patent/JP2021527083A/ja active Pending
- 2019-06-12 WO PCT/US2019/036725 patent/WO2019241353A1/en not_active Ceased
- 2019-06-12 TW TW108120366A patent/TW202011954A/zh unknown
- 2019-06-12 SG SG11202012426WA patent/SG11202012426WA/en unknown
- 2019-06-12 EP EP19819797.2A patent/EP3806842A4/en not_active Withdrawn
- 2019-06-12 BR BR112020025452-5A patent/BR112020025452A2/pt not_active Application Discontinuation
- 2019-06-12 MX MX2020013535A patent/MX2020013535A/es unknown
- 2019-06-12 CN CN201980053303.0A patent/CN112566634A/zh active Pending
- 2019-06-12 AU AU2019284765A patent/AU2019284765A1/en not_active Abandoned
- 2019-06-12 KR KR1020217000898A patent/KR20210020098A/ko not_active Withdrawn
- 2019-06-12 CA CA3103245A patent/CA3103245A1/en active Pending
-
2020
- 2020-12-10 CL CL2020003204A patent/CL2020003204A1/es unknown
- 2020-12-10 US US17/117,485 patent/US20210113656A1/en not_active Abandoned
- 2020-12-10 IL IL279353A patent/IL279353A/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527083A5 (enExample) | ||
| Oki et al. | Preventive effect of Goshajinkigan on peripheral neurotoxicity of FOLFOX therapy (GENIUS trial): a placebo-controlled, double-blind, randomized phase III study | |
| Dorsey et al. | Promising new molecular targeted therapies in head and neck cancer | |
| CN111065411B (zh) | Pd-1抗体和vegfr抑制剂联合治疗小细胞肺癌的用途 | |
| US20180036395A1 (en) | Dosage and administration of monospecific and bispecific anti-igr-1r and anti-erbb3 antibodies | |
| BR122023025321A2 (pt) | Uso de anticorpos anti-b7-h1 e anti-ctla-4 | |
| KR20220162843A (ko) | 종양 치료용 항-ｂ7-ｈ1 항체 | |
| JP2018512402A5 (enExample) | ||
| JP2021529777A5 (enExample) | ||
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| JP2021523096A5 (enExample) | ||
| JP2021530502A5 (enExample) | ||
| JP2008500964A5 (enExample) | ||
| JP2022501332A5 (enExample) | ||
| CN109806393B (zh) | 抗pd-1抗体、培美曲塞和铂类药物联合治疗非小细胞肺癌的用途 | |
| JP2024521105A5 (enExample) | ||
| TW202313694A (zh) | 治療癌症以及腫瘤相關之體重減輕及惡病質之方法 | |
| JP2021528399A5 (enExample) | ||
| JP2024513247A5 (enExample) | ||
| WO2025103379A1 (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 | |
| CN120437318A (zh) | 抗体药物偶联物和免疫检查点抑制剂的联合应用 | |
| JP2025504278A5 (enExample) | ||
| CN110859959A (zh) | 抗pd-1抗体联合紫杉醇和铂类化合物在制备治疗食管癌的药物中的用途 | |
| JP2024519450A5 (enExample) | ||
| CN110013552B (zh) | 抗pd-1抗体、吉西他滨和铂类药物联合治疗恶性胆道肿瘤的用途 |